139 related articles for article (PubMed ID: 36549254)
1. Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer.
Wang P; Zhu H; Liu J; Xie S; Xu S; Chen Y; Xu J; Zhao Y; Zhu Z; Xu J
Bioorg Chem; 2023 Feb; 131():106327. PubMed ID: 36549254
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.
Sun Y; Wang R; Sun Y; Wang L; Xue Y; Wang J; Wu T; Yin W; Qin Q; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Jul; 237():114373. PubMed ID: 35486993
[TBL] [Abstract][Full Text] [Related]
3. Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein.
Qi Z; Yang G; Deng T; Wang J; Zhou H; Popov SA; Shults EE; Wang C
Bioorg Chem; 2021 Jun; 111():104901. PubMed ID: 33878647
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of KRAS
Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
[TBL] [Abstract][Full Text] [Related]
5. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
6. Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT.
Cheng J; He S; Xu J; Huang M; Dong G; Sheng C
J Med Chem; 2022 Dec; 65(23):15725-15737. PubMed ID: 36442664
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment.
Gan X; Wang F; Luo J; Zhao Y; Wang Y; Yu C; Chen J
Eur J Pharm Sci; 2024 Jan; 192():106624. PubMed ID: 37898394
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
10. CRBN ligand expansion for hematopoietic prostaglandin D
Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.
Wang S; Luo D; Pu C; Ma X; Zhang H; Feng Z; Deng R; Yu S; Liu Y; Huang Q; Li R
Eur J Med Chem; 2023 Feb; 248():115082. PubMed ID: 36628851
[TBL] [Abstract][Full Text] [Related]
12. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src.
Manda S; Lee NK; Oh DC; Lee J
Molecules; 2020 Apr; 25(8):. PubMed ID: 32340152
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a miniaturized PROTAC with potent activity and high selectivity.
Gong L; Li R; Gong J; Ning X; Sun J; Ma Q; Zhu C; Yang Y; Lin K; Li Y; Zhang Q; Li T; Lin Z
Bioorg Chem; 2023 Jul; 136():106556. PubMed ID: 37105002
[TBL] [Abstract][Full Text] [Related]
15. Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4.
Zhu L; Hu S; Yan X; Zeng Q; Zhang B; Jiang L; Yao SQ; Ge J
Bioorg Chem; 2023 May; 134():106461. PubMed ID: 36924654
[TBL] [Abstract][Full Text] [Related]
16. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
[TBL] [Abstract][Full Text] [Related]
17. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent small molecule PROTACs targeting mutant EGFR.
Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
[TBL] [Abstract][Full Text] [Related]
20. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
